Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LaSara Medical Group vs Remi Meds

LaSara Medical Group
Graded #455

Higher grade

vs+6.100000000000001
Remi Meds
Graded #493

Lower grade

The verdict

LaSara Medical Group takes it — 54.5/100 to 48.4/100.

LaSara Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LaSara Medical Group is a national telehealth provider with in-person availability in southern California, offering compounded semaglutide and tirzepatide alongside a broader menu of TRT, NAD+, sermorelin,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRemi Meds +1
33
34
Dose & formulationLaSara Medical Group +10
64
54
Clinical oversightLaSara Medical Group +15
69
54
Labs & monitoringLaSara Medical Group +3
53
50
FulfillmentLaSara Medical Group +13
66
53
Contract termsRemi Meds +8
47
55
LaSara Medical Group · left barRemi Meds · right bar

The numbers

MetricLaSara Medical GroupRemi Meds
WeighScore54.5/10048.4/100
GradeCC
Scorecard rank#455#493
Semaglutide$289/mo (compounded)$249/mo (0.25 mg dose, compounded)
Tirzepatide$399/mo (bundle, compounded)$349/mo (2.25 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
LaSara Medical Group

Graded #455 · C

Strengths

  • Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
  • National telehealth plus an in-person option in Southern California — uncommon hybrid model
  • Free initial consultation
  • Active promotional pricing (30% off sitewide at the time of review)
  • GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy partner not named
  • LegitScript certification status not confirmed
  • Per-state availability not listed despite the national-telehealth claim
  • Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard